Company intelligence / Profile preview
YSOPIA Bioscience
Bordeaux, Franceysopia.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
YSOPIA successfully completed the Phase 1 clinical study for its Xla1 biotherapy in July 2021 and demonstrated excellent safety and tolerability profile, as well as first biological activity.
- Therapeutic areas
- GastroenterologyPsychiatryMetabolic DisordersEndocrinologyImmunologyOncology
- Modalities
- BiotherapiesSingle-strain keystone bacteriaMicrobiota
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on YSOPIA Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YSOPIA Bioscience.